Receptor profile — the key difference
Tirzepatide is a dual incretin agonist engaging GLP-1 and GIP receptors. Retatrutide adds glucagon-receptor activity to create a triple agonist profile (GLP-1 + GIP + glucagon). In research literature this third target is associated with distinct metabolic and energy-expenditure signalling pathways.
Half-life and pharmacokinetics
Both compounds are engineered for extended half-life suitable for less-frequent administration intervals in research models. Tirzepatide's terminal half-life is reported in the five-day range in metabolic-research literature. Retatrutide's terminal half-life is reported in the six-to-seven-day range, reflecting the additional sequence engineering required for triple-receptor engagement. These figures are assay- and model-dependent — always cross-reference the primary literature for your specific experimental design.
Receptor affinity and selectivity
Tirzepatide's affinity ratio between GLP-1 and GIP receptors is tuned to balance glucose-dependent insulin secretion with gastric-emptying modulation. Retatrutide introduces glucagon-receptor affinity at a lower relative potency than its GLP-1 and GIP components, a profile designed to explore hepatic glucose-output and lipid-oxidation endpoints without overwhelming counter-regulatory pathways. Research teams comparing the two typically note that retatrutide's triple profile shifts the focus from purely glycaemic endpoints toward broader energy-balance research models.
Sequence and structural notes
Both peptides are synthetic sequences delivered as lyophilised powders. Tirzepatide's sequence incorporates a C20 fatty-diacid moiety for albumin binding and extended half-life. Retatrutide uses a similar acylation strategy but with sequence modifications that enable the additional glucagon-receptor engagement while preserving the GLP-1 and GIP activity. Sequence-sensitive assay work should always verify identity by mass spectrometry before quantitative use.
Handling and storage
Both compounds follow the same standard research-peptide handling: lyophilised storage at 2–8°C, reconstitution with bacteriostatic water and refrigerated in-use stability. Because retatrutide and tirzepatide are long-acting sequences, in-use stability windows are especially important — any reconstituted material past its stability window should be discarded rather than used in a protocol.
Batch documentation
Every Regena batch of retatrutide and tirzepatide ships with independent HPLC purity, mass-spec identity confirmation and a lot-matched COA. Given the sequence complexity of both compounds, purity figures should be reviewed alongside identity confirmation before any quantitative assay work.
Choosing for a research protocol
Tirzepatide is typically referenced in protocols focused on dual incretin pathways — GLP-1/GIP co-agonism, gastric emptying and glucose-dependent insulin secretion. Retatrutide is typically referenced when the research model benefits from the addition of glucagon-receptor signalling — hepatic glucose output, energy expenditure or lipid-metabolism endpoints. Both are available in the Peptide Library with current batch data.
Frequently asked questions
Are retatrutide and tirzepatide the same peptide?+
No. They are distinct synthetic sequences with different receptor profiles, molecular weights and pharmacokinetic properties.
Does retatrutide replace tirzepatide in research?+
Not necessarily — they target different research questions. Dual agonism and triple agonism are complementary rather than interchangeable model tools.
Which has the longer half-life?+
Research literature generally reports retatrutide's terminal half-life as slightly longer than tirzepatide's, though both are in the multi-day range and assay-dependent.
Where can I review the COA?+
Lot-matched COAs for retatrutide and tirzepatide are published on the lab reports page.